BioStock: Promore Pharma’s CEO on hopes for 2023

For Solna-based Promore Pharma, 2022 was characterised by steady advancement in the development of its drug candidate ensereptide. During the year, the company carried out a significant part of a phase II study with the candidate, which is being developed to inhibit scarring on the skin. At the same time, preparations for phase III studies are ongoing for the second candidate, ropocamptide. BioStock contacted CEO Jonas Ekblom to find out more about the company’s goals for 2023.

Read the article at biostock.se:

https://www.biostock.se/en/2023/01/promore-pharmas-ceo-on-hopes-for-2023/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/